

1 **COVID-19 severity is associated with immunopathology and**
2 **multi-organ damage**

3

4 Running Title: Insight of pathophysiology of COVID-19

5

6 Yan-Mei Chen^{1,4}, Yuanting Zheng^{1,4}, Ying Yu^{1,4}, Yunzhi Wang^{1,4}, Qingxia Huang^{1,4}, Feng
7 Qian^{1,4}, Lei Sun^{2,4}, Zhi-Gang Song¹, Ziyin Chen¹, Jinwen Feng¹, Yanpeng An¹, Jingcheng
8 Yang¹, Zhenqiang Su¹, Shanyue Sun¹, Fahui Dai¹, Qinsheng Chen¹, Qinwei Lu¹, Pengcheng
9 Li¹, Yun Ling¹, Zhong Yang¹, Huiru Tang¹, Leming Shi¹, Li Jin¹, Edward C. Holmes³, Chen
10 Ding^{1*}, Tong-Yu Zhu^{1*}, Yong-Zhen Zhang^{1*}

11

12 ¹Shanghai Public Health Clinical Center, State Key Laboratory of Genetic Engineering,
13 School of Life Sciences and Human Phenome Institute, Fudan University, Shanghai, China.

14 ²Institute of Developmental Biology and Molecular Medicine, Fudan University, Shanghai,
15 China.

16 ³Marie Bashir Institute for Infectious Diseases and Biosecurity, School of Life and
17 Environmental Sciences and School of Medical Sciences, The University of Sydney, Sydney,
18 New South Wales, Australia.

19

20 ⁴These authors contributed equally: Yan-Mei Chen, Yuanting Zheng, Ying Yu, Yunzhi Wang,
21 Qingxia Huang, Feng Qian, Lei Sun

22 *Correspondence to: Yong-Zhen Zhang, Email: zhangyongzhen@shphc.org.cn;

23 Tong-Yu-Zhu, Email: zhutongyu@shphc.org.cn; Chen Ding, Email: chend@fudan.edu.cn.

24 **Abstract**

25 COVID-19 is characterised by dysregulated immune responses, metabolic dysfunction and
26 adverse effects on the function of multiple organs. To understand how host responses
27 contribute to COVID-19 pathophysiology, we used a multi-omics approach to identify
28 molecular markers in peripheral blood and plasma samples that distinguish COVID-19
29 patients experiencing a range of disease severities. A large number of expressed genes,
30 proteins, metabolites and extracellular RNAs (exRNAs) were identified that exhibited strong
31 associations with various clinical parameters. Multiple sets of tissue-specific proteins and
32 exRNAs varied significantly in both mild and severe patients, indicative of multi-organ damage.
33 The continuous activation of IFN-I signalling and neutrophils, as well as a high level of
34 inflammatory cytokines, were observed in severe disease patients. In contrast, COVID-19 in
35 mild patients was characterised by robust T cell responses. Finally, we show that some of
36 expressed genes, proteins and exRNAs can be used as biomarkers to predict the clinical
37 outcomes of SARS-CoV-2 infection. These data refine our understanding of the
38 pathophysiology and clinical progress of COVID-19 and will help guide future studies in this
39 area.

40

41 **Key words:** SARS-CoV-2 / COVID-19 pathophysiology / multiple organ damage /
42 immunopathogenesis / multi-omics

43

44 **Introduction**

45 Coronaviruses (family *Coronaviridae*) are a diverse group of positive-sense single-stranded
46 RNA viruses with enveloped virions (Cui et al., 2019; Masters and Perlman, 2013).
47 Coronaviruses are well known due to the emergence of Severe Acute Respiratory Syndrome
48 (SARS) in 2002–2003 and Middle East Respiratory Syndrome (MERS) in 2012, both of which
49 caused thousands of cases in multiple countries (Bermingham et al., 2012; Cui et al., 2019;
50 Ksiazek et al., 2003). Coronaviruses naturally infect a broad range of vertebrate hosts
51 including mammals and birds (Cui et al., 2019). As coronavirus primarily target epithelial cells,
52 they are generally associated with gastrointestinal and respiratory infections (Cui et al., 2019;
53 Masters and Perlman, 2013). In addition, they cause hepatic and neurological diseases of
54 varying severity (Masters and Perlman, 2013).

55 The world is currently experiencing a disease pandemic (COVID-19) caused by a newly
56 identified coronavirus called SARS-CoV-2 (Wu et al., 2020a). At the time of writing, there
57 have been more than 6 million cases of SARS-CoV-2 and over 387,000 deaths globally
58 (WHO, 2020). The disease leads to both mild and severe respiratory manifestations, with the
59 latter prominent in the elderly and those with underlying medical conditions such as
60 cardiovascular and chronic respiratory disease, diabetes, and cancer (Guan et al., 2020). In
61 addition to respiratory syndrome, mild gastrointestinal and/or cardiovascular symptoms as
62 well as neurological manifestations have been documented in hospitalized COVID-19 patients
63 (Mao et al., 2020). Combined, these data point to multiple organ failures, and hence that
64 COVID-19 pathogenesis is complex, especially in patients experiencing severe disease.

65 It is believed that SARS-COV-2 is able to use angiotensin-converting enzyme 2 (ACE 2)
66 as a receptor for cell entry (Zheng et al., 2020; Zhou et al., 2020b). ACE2 is attached to the
67 outer surface (cell membranes) of cells in the lungs, arteries, heart, kidney, and intestines
68 (Hamming et al., 2004). Additionally, ACE2 is expressed in Leydig cells in the testes (Jiang et
69 al., 2014) and neurological tissue (Baig et al., 2020). As such, it is possible that these organs
70 might also be infected by SARS-CoV-2. The host immune response to SARS-CoV-2 may also
71 impact pathogenicity, resulting in severe tissue damage and, occasionally, death. Indeed,
72 several studies have reported lymphopenia, exhausted lymphocytes and cytokine storms in
73 COVID-19 patients (Blanco-Melo et al., 2020; Cao, 2020). Numerous clinical studies have
74 also observed the elevation of lactate dehydrogenase (LDH), IL-6, troponin I, inflammatory
75 markers and D-dimer in COVID-19 patients (Wang et al., 2020b; Zhou et al., 2020a). However,
76 despite the enormous burden of morbidity and mortality due to COVID-19, we know little
77 about its pathophysiology, even though this establishes the basis for successful clinical
78 practice, vaccine development and drug discovery.

79 Using a multi-omics approach employing cutting-edge transcriptomic, proteomic and
80 metabolomic technologies we identified significant molecular alterations in patients with
81 COVID-19 compared to uninfected controls in this study. Our results refine the molecular view
82 of COVID-19 pathophysiology associated with disease progression and clinical outcome.

83

84 **Results**

85 **Patient cohort and clinical characters**

86 We studied 66 clinically diagnosed and laboratory confirmed COVID-19 patients hospitalized
87 at the Shanghai Public Health Clinical Center, Shanghai, China between January 31st and
88 April 7th, 2020 (Fig. 1A, Tables S1 and S2). At the time of writing, 55 (49 mild and 6 severe) of
89 the 66 patients have recovered and been discharged following treatment, while five patients
90 (1 mild and 4 severe) remain in the hospital and are receiving ongoing treatment.
91 Unfortunately, six patients (all severe) died.

92 **Molecular variation associated with COVID-19 pathophysiology**

93 Serial blood and throat swab samples were collected from all patients, as well as from 17
94 healthy volunteers. To determine whether COVID-19 pathophysiology was associated with
95 particular molecular changes, a total of 23,373 expressed genes, 9,439 proteins, 327
96 metabolites and 769 exRNAs were examined using a multi-omics approach combining
97 transcriptomics, proteomics, and metabolomics (Fig. 1B). Compared with healthy controls,
98 mild and severe patients had significantly different expression patterns (higher or lower) in
99 6.79% and 26.0% of expressed genes, 52.1% and 51.7% of proteins, 7.34% and 15.6% of
100 metabolites and 39.9% and 20.5% of exRNAs, respectively (Fig. 1C, Tables S3-S6).
101 Significant differences in the principal component 1 (PC1), PC2 and/or PC3 between healthy
102 controls, mild and severe COVID-19 patients were observed (Figs. 2A and S1A). Remarkably,
103 there were significant correlations between multi-omics data and classical blood and
104 biochemical parameters (Fig. 2B), suggesting that the molecular changes identified directly
105 impact the pathophysiology of COVID-19.

106 The correlation between molecular variation and COVID-19 pathophysiology was best
107 reflected in the proteomic analysis (Fig. 2). Specifically, there was significant downregulation
108 in the tricarboxylic acid cycle (TCA) and glycolytic pathways in both mild and severe patients
109 compared to healthy controls (Figs. 2C and S1B). However, the hypoxia-inducible factors
110 (HIF-1) signaling pathways and well-known host defense pathways (e.g., T cell receptor
111 signaling pathway, ISG15 antiviral signaling pathway) were elevated in these patients (Figs.
112 2C and S1B). Additionally, we identified 14 co-expression groups (“modules”) of proteins that
113 were highly correlated to clinical parameters (Fig. 2D). Module 1, comprising 12 proteins, was
114 strongly associated with activated partial thromboplastin time (APTT) (Fig. 2E), with their
115 downregulated expression likely indicating higher APTT values. In contrast, levels of plasma
116 IL-6 and IL-10 in patients were positively correlated with the expression of proteins in module
117 15 (Fig. 2F). Notably, correlations between the proteins in these modules were also identified,
118 suggesting that proteins may interact in defining clinical outcome (Figs. S2C and S2D). In
119 addition to proteins, lipoprotein variation was also significantly correlated with immune
120 changes including IgG, monocytes and procalcitonin (Fig. 2B). Combined, these data reveal a
121 significant association between specific molecular variations and COVID-19 pathophysiology.

122 **Tissue damage caused by SARS-CoV-2**

123 Recent data suggests that SARS-CoV-2 infection is associated with multi-tissue injury and
124 organ damage (Wu et al., 2020b; Zheng et al., 2020). Compared to healthy controls, intensive
125 alteration of tissue-enhanced proteins were observed in all COVID-19 patients, suggestive of
126 multiple organ dysfunction including the lung, liver, brain, testis and intestine (Figs. 3A and 3I).

127 Notably, the majority of proteins related to organ function were downregulated in COVID-19
128 patients (Fig. 3B). As expected, lung-enhanced proteins varied significantly in the plasma of
129 both mild and severe patients. Likely because lung-enhanced proteins are not rich in the
130 human protein atlas, the lung-enhanced proteins in either mild or severe patients did not
131 achieve the top rank. Nevertheless, lung abnormality was reflected in the activation of the
132 HIF-1 signaling pathway and reactive oxygen species metabolic processes in all patients (Fig.
133 3D). Liver- and brain-enhanced proteins also varied significantly, followed by those from the
134 testis, intestine and other organs, suggesting that these organs might also be seriously
135 affected (Fig. 3A). Severe brain dysfunction was reflected in the significant decline of
136 brain-enhanced proteins regulating neurotransmitter synthesis, neurotransmitter transport,
137 and the numbers of neurotransmitter receptors, as well as a significant decrease in proteins
138 including ENO1, MBP and NEFM that are known biomarkers to reflect brain dysfunction (Figs.
139 3C and 3F). Liver-enhanced proteins, that regulate the transportation of sterol and cholesterol,
140 were downregulated, while those involved in acute inflammatory response were elevated in
141 both mild and severe patients (Fig. 3E). Testis-enhanced proteins involved in the cell cycle and
142 cell proliferation were upregulated in all male patients, although proteins (e.g. YBX2)
143 associated with reproduction were significantly downregulated. Heart specific proteins related
144 to cardia muscle contraction and oxidative reduction were reduced in COVID-19 patients (Fig.
145 3H). Finally, variation in tissue-enhanced proteins was also associated with COVID-19 severity.
146 For example, brain-enhanced proteins enriched in tubulin accumulation were upregulated in
147 mild disease patients, indicating multiple neuron cell apoptosis in these patients. However,

148 proteins significantly upregulated in severe patients were enriched in liver steatosis AOP and
149 in multi-drug resistance factors (Figs. S2A and S2B).

150 Organ dysfunction was also reflected in the relative proportion of different cell
151 populations. We identified 16 cell types whose abundance changed significantly following
152 virus infection (Fig. 3F). For example, the set of proteins expressed by alveolar type 1/2
153 epithelial cells (AT1 and AT2) were significantly downregulated in all patients (Fig. 3G). In
154 addition, the majority of tissue-injury related exRNAs across all tissues showed differential
155 expression, including lung (55 in 92 pre-identified, $p < 0.0001$), kidney (14 in 22, $p < 0.0001$),
156 liver (17 in 22, $p < 0.0001$), brain (8 in 16, $p = 0.0016$) and heart (5 in 6, $p < 0.0001$) (Fig. S2C).
157 Furthermore, a large proportion of tissue-injury related exRNAs were expressed differently in
158 mild and severe patients in most tissues analyzed (30/92 in lung, 10/22 in kidney, 8/22 in liver
159 and 3/6 in heart), except brain (1/16) (data not shown). Together, our data indicate that
160 COVID-19 causes adverse functions in multiple organs including lung damage.

161 **Immunopathological changes in COVID-19 patients**

162 Immune responses can cause severe damage to the cells or tissues that defend hosts against
163 viral infection (Baseler et al., 2017; Cicchese et al., 2018; Newton et al., 2016). Analysis of
164 whole blood transcriptomic data revealed that gene sets, including an antiviral IFN signature
165 (M75 module), were enriched at the first sampling timepoint (Fig. 4A, Table S7). Notably, IFN
166 signaling was continuously activated in severe patients during the entire period of
167 hospitalization (Fig. 4A), while negative regulators of innate immune signaling (e.g. TRIM59,
168 USP21 and NLRC3) were downregulated (Fig. S3A). Additionally, significant increases of IL-6,

169 IL-8 and IL-10 levels were detected in severe patients compared to mild patients (Figs. 2F
170 and S3B). Combined, these data suggest that the continuous activation of IFN-I signaling and
171 a high level of inflammatory cytokines likely impact COVID-19 immunopathology.

172 Higher neutrophil counts were observed in severe patients but not in mild patients during
173 hospitalization (Fig. S3C). Examination of the neutrophil transcriptomic signatures revealed
174 that excessive neutrophil activation was associated with severe rather than mild disease.
175 These markers involved those utilized in neutrophil chemotaxis, activation and migration (Fig.
176 S3D). Notably, genes encoding molecules associated with neutrophil extracellular traps
177 (NETs) were significantly upregulated in severe disease patients (Fig. 4B). As excess NETs
178 formation can lead to tissue damage (Kruger et al., 2015), our data imply that the excessive
179 activation of neutrophils may contribute to COVID-19 pathogenesis.

180 As in the case of influenza viruses that can be cleared by strong T cell responses (van de
181 Sandt et al., 2014; Wang et al., 2015), SARS-CoV-2 immunity in mild patients was
182 characterized by a robust T cell response, reflected in T cell signaling activation (M7.3 module,
183 M35.1 module) and T cell differentiation (M19 module) on admission, followed by subsequent
184 rapid reduction (Fig. 4A). However, severe patients lost ~59.1% of their total T cell population,
185 62.3% of their CD4 T cells and 52.8% of their CD8 T cells. Importantly, the CD4 T cell
186 population gradually recovered in the severe-survivors compared to the severe-fatality group
187 (Fig. S3E). Additionally, T cells in the survivors were primed by dendritic cells and expressed
188 high levels of *IFNG* and *GZMB* (Fig. 4C). T cell dysfunction was observed in the severe group,
189 which could in part be due to an inhibitory status based on the expression levels of multiple

190 exhaustion markers (Fig. S3F). Strikingly, the severe disease group had a greater abundance
191 of *ARG1* (Fig. S3G). Finally, the mild group had higher TCR diversity than the severe group
192 (Fig. S3H). In sum, our data suggest that the T cell response is indispensable to successful
193 host defense against SARS-CoV-2.

194 Finally, we investigated the immune signatures associated with poor COVID-19
195 prognosis. Notably, KEGG functional analysis revealed that gene sets of the “IL-17 signaling
196 pathway” were significantly enriched in the severe-fatality group. Further analysis of the
197 signature components revealed that p38 MAPK activation was dominant in fatal cases, while
198 higher levels of IL13 and IFNG were present in survivors (Fig. 4D). These gene signatures
199 might contribute to greater neutrophil influx (CXCL2 and CXCL6) and inflammation (S100A8),
200 and could be detrimental in the severe disease group (Fig. 4E).

201 **Comprehensive changes in lipoprotein metabolism in COVID-19 patients**

202 To reveal metabolic changes in COVID-19 patients, we quantified 348 metabolite parameters
203 in small metabolites, lipoprotein subclasses and their compositional components. The PCA
204 scores plot revealed an obvious metabolomic trajectory from mild to severe COVID-19, and
205 gradually away from healthy controls (Fig. 5A). Such group-clustering patterns were
206 independently confirmed by PCA scores plots from all NMR-detectable metabolite signals, all
207 MS-detectable signals for lipids, and hydrophilic molecules in plasma samples (Figs.
208 S4A-S4D). Our data therefore indicate that a concentration of changes in plasma metabolites
209 are associated with COVID-19 severity.

210 Further statistical analyses highlighted the major changes in the levels of lipoprotein
211 sub-classes and their compositional components including LDL1 (L1TG), LDL4, VLDL5,
212 HDL1 and HDL4 (Figs. 5C and S4E). Compared with healthy controls, the level of
213 triglycerides (TG) in LDL1 and free cholesterol (FC) in all VLDL5 lipids were significantly
214 elevated in both mild and severe patients, while there were significant decreases in LDL4 and
215 LDL5, cholesterol in LDL, cholesterol esters in VLDL5, Apo-A2 in both HDL and nascent HDL,
216 FC in HDL1 together with total cholesterol and phospholipids (PL). Interestingly, HDL4 and its
217 components had significant lower levels in severe patients. Compared with mild patients,
218 L1TG and PL in HDL1 was increased in severe patients, while cholesterol in HDL1 and HDL2,
219 HDL4 and its components decreased (Fig. S4F). Fortunately, most of these lipoproteins
220 recovered following patients discharge (Figs. 5B, 5C and S4D).

221 The levels of some key proteins involved in lipoprotein metabolism, including the
222 soluble low-density lipoprotein receptor (sLDLR), lecithin-cholesterol acyltransferase (LCAT)
223 and the cholesteryl-ester transfer protein (CETP), were significantly reduced in mild and
224 severe COVID-19 patients than those in healthy controls (Figs. 5D and 5E). Additionally,
225 enzymes such as ACO2, IDH, OGDH, DLD, SDH and MDH in the TCA cycle were lower in
226 COVID-19 patients compared to healthy controls, while the enzymes central to fatty acid
227 synthesis (Acetyl coenzyme A carboxylase [ACAC] and Fatty acid synthetase [FASN]) were
228 elevated. Finally, significant concurrent elevations in plasma lactate and LDH were
229 observable in patients compared to healthy controls (Figs. 5E, S4G and S4H). In sum, these

230 data reveal the dysregulation in lipoprotein metabolism, glycolysis and TCA cycle during
231 SARS-CoV-2 infection.

232 **Viral load is associated with disease prognosis of severe COVID-19 patients**

233 The severity and clinical outcome of COVID-19 were also associated with viral load. Overall,
234 SARS-CoV-2 RNA loads on admission were significantly higher in the throat swabs of the five
235 fatal cases compared to those who survived (mean, 1.26×10^5 vs 3.98×10^3 copies/mL,
236 respectively; $p = 0.04$) (Fig. 6A). Although viral load declined during the period of
237 hospitalization in both survival and fatal cases, it remained elevated in fatal cases compared
238 to survivors.

239 Estimation of the correlation coefficient between viral load and protein expression
240 revealed that proteins participating in antiviral processes, including the TCR and BCR
241 signaling pathway, were positively associated with viral load changes in severe-survivors.
242 Additionally, proteins participating in viral life cycle processes, including viral messenger RNA
243 synthesis and innate immune responses, were only positively associated with viral load
244 changes in the severe-fatal group (Fig. 6E). Notably, proteins (e.g., FASN, ACSS2, CPT1A,
245 HADHB) involved in pathways including mitochondrial function, lipid metabolic process,
246 steroid hormone process and TCA cycle were continuously upregulated in the severe-survivor
247 compared to the severe-fatal group (Figs. 6B and 6C). However, this upregulation was only
248 observed during the early stage following admission in the severe-fatal group. Surprisingly,
249 proteins related to viral life cycle, viral RNA synthesis, oxidative stress (e.g., EIF, EIFB,
250 RPL19, SLCA24), were downregulated in the several-survivor cases following admission, but

251 maintained high levels in the severe-fatal patients (Figs. 6B and 6D). Hence, SARS-CoV-2
252 may exploit host resources over the duration of its infection.

253 **Biomarkers predictive of clinical outcomes of COVID-19 patients**

254 As many molecules associated with COVID-19 pathophysiology were identified, we
255 investigated whether particular molecular changes could be used as biomarkers to predict
256 clinical outcomes. Using an unsupervised PCA, the exRNA, mRNA, proteomics and the
257 corresponding clinical covariate data sets across all time-points, or a subset from the first
258 time-point, clustered into three clinical phenotypes: (i) samples from healthy controls; (ii)
259 samples from COVID-19 patients with a good prognosis; and (iii) samples from COVID-19
260 patients with a poor prognosis (Methods; Fig. 7A). Given this, prognostic classification models
261 were constructed. Predictive models based on all four types of data worked well, especially
262 those utilizing the clinical covariates and the proteomic data (Fig. S5), suggesting that all four
263 types of data collected at admission contain key prognostic information.

264 In addition, we identified robust predictive models and prognostic biomarkers from
265 each of the four types of data using a previously described approach (Shi et al., 2010) (Figs.
266 7B and 7C). One or two features (expressed genes, proteins, exRNAs, and biochemical
267 parameters) in each data set were able to clearly separate patients into two groups
268 characterized by different prognoses (Figs. 7D-7I). Poor prognosis was associated with
269 increased levels of D-dimer ($p=0.004$) and fibrinogen degradation products (FDP; $p=0.02$),
270 and with a decrease in F13A1 expression ($p<0.002$; Figs. 7H and 7I), suggesting that blood
271 clotting status may be one of the key factors to monitor in COVID-19 progression. For the

272 mRNA-based model, poor prognosis was associated with lower levels of CD3E and higher
273 levels of OLAH, and hence highly concordant with immune responses in COVID-19 patients
274 (Fig. 7E). Additionally, exRNA-based predictors included members of the let-7 family (Figs.7D
275 and 7E). Finally, the protein-based models highlighted features enriched in extracellular
276 exosomes, lipoprotein metabolic processes, innate immune responses, and blood
277 coagulation (Figs. 7G and 7H).

278

279 **Discussion**

280 The COVID-19 pandemic has had a profound impact on a global scale (WHO, 2020). Despite
281 the enormous burden or morbidity and mortality due to COVID-19, we know little about its
282 pathophysiology, even though this establishes the basis for successful clinical practice,
283 vaccine development and drug discovery. Current clinical practice may be unable to provide a
284 precision supportive therapy when a novel disease like COVID-19 emerges, in part explaining
285 the high case fatality rates often observed at the beginning of outbreaks (Alonso et al., 2019).
286 We used a multi-omics approach to identify numerous expressed genes, proteins,
287 metabolites and exRNAs from COVID-19 patients with a range of disease severities, and that
288 were significantly correlated with key clinical features as well as to classic blood and
289 biochemical parameters (Fig. 2). These data therefore provide a comprehensive molecular
290 view of the pathophysiology of COVID-19. Finally, based on our multi-omics data (Fig. S6),
291 mild and severe COVID-19 cases may need different therapeutic strategies.

292 COVID-19 severity and clinical outcome was significantly associated with multi-organ
293 damage. Due to the widespread presence of ACE2 in humans (Chai et al., 2020; Chen et al.,
294 2020b; Fan et al., 2020; Hamming et al., 2004; Zou et al., 2020), SARS-CoV-2 is able to infect
295 many organs (Wadman et al., 2020). In addition to pneumonia (Wu et al., 2020a; Zhou et al.,
296 2020b), several clinical studies have reported mild gastrointestinal, cardiovascular symptoms
297 and neurological manifestations in hospitalized COVID-19 patients (Baig, 2020; Chen et al.,
298 2020a; Guan et al., 2020; Mao et al., 2020; Xiang et al., 2020; Xu et al., 2020).

299 Histopathologic investigation has also described damage in other organs in addition to the
300 lung (Barton et al., 2020; Cai et al., 2020; Wadman et al., 2020; Wang et al., 2020c). The
301 molecular data generated here support the occurrence of damage in multiple organs including
302 lung, liver, brain, heart in COVID-19 patients, and also identify damage in other organs
303 including the testis (Fig. 3). In the case of brain and testis damage, a key issue is how
304 SARS-CoV-2 is able to cross the blood-brain or the blood-testis barriers? One possibility
305 might be that heparin was prescribed for coaggregation problems commonly observed in
306 some COVID-19, even though it increases permeability (Gautam et al., 2001; Lin et al., 2020;
307 Oschatz et al., 2011). More importantly, the alteration (up- or down-regulated) of
308 tissue-enhanced proteins and tissue-damage related exRNAs are significantly correlated with
309 clinical severity and outcome.

310 SARS-CoV-2 infection results in acute lung injury (ALI) in patients, with ground-glass
311 opacity in most computed tomography (CT) reports from our facility and in other hospitals
312 (Chen et al., 2020a; Zhou et al., 2020b; Zhu et al., 2020). Autopsy disclosed histologic

313 changes in lungs included edema, fibrinous/proteinaceous exudates, hyperplastic
314 pneumocytes, patchy inflammation, multinucleated giant cells and diffuse alveolar damage
315 (Barton et al., 2020; Tian et al., 2020). The data generated here revealed that the number of
316 AT1 and AT2 cells reduced significantly in severe patients, suggesting destruction of the
317 alveolar epithelium (Fig. 3F), which in turn will lead to the accumulation alveolar fluid and
318 hence cause hypoxia (Vadász and Sznajder, 2017). In addition, we also noted that HIF1a
319 signaling was modified which may further worsen ALI (Dada et al., 2003). Thus, our molecular
320 data suggest that removal of excess alveolar fluid and the restoration of alveolar structure will
321 be of major clinical importance.

322 Our data also identified immune pathophysiology a factor that greatly impacted
323 COVID-19 clinical outcome. The innate immune response against viruses is mounted
324 immediately after a host acquires a viral infection, whereas there is a delay before the onset of
325 adaptive immunity (Murphy and Weaver, 2016). Unlike SARS-CoV and influenza virus,
326 SARS-CoV-2 may be present in patients for longer time periods, especially those with severe
327 syndrome (Du et al., 2020; Wang et al., 2020a). Several studies have reported that severe
328 COVID-19 patients experienced lymphopenia, impaired adaptive immunity, uncontrolled
329 inflammatory innate responses, and cytokine storms (Guan et al., 2020; Huang et al., 2020;
330 Qin et al., 2020; Shi et al., 2020; Wang et al., 2020b). While it is believed that T cells play an
331 important role in fighting the infection in the case of Ebola virus, influenza virus and
332 SARS-CoV (Channappanavar et al., 2014; Ruibal et al., 2016; Sridhar et al., 2013; van de

333 Sandt et al., 2014; Zhao et al., 2010), a role for T cells in SARS-CoV-2 infection not yet has
334 been determined, likely reflecting “lymphopenia” (Wang et al., 2020d; Zhou et al., 2020c).

335 Our longitudinal analyses provided evidence that patients with mild or severe symptoms
336 who succeeded in T cell mobilization promptly controlled SARS-CoV-2 infection and
337 symptoms (Figs. 2C, 4A and 4C). In contrast, those (especially severe-fatal) patients that
338 failed to mount a sound T cell response maintained a continuous pro-inflammatory response
339 and suffered from cytokine storms as well as excess NETs (Figs. 4A and 4B), both of which
340 are known to cause systematic tissue damages (Akiyama et al., 2019; Bohmwald et al., 2019).
341 In sum, our data indicate that T cells play a key role in controlling SARS-CoV-2 infection.

342 It is believed that p38 signaling, collagenase (MMP9), neutrophil chemo-attractants
343 (CXCL2 and CXCL6) and S100A8 are autoinflammation-like signatures (Cheng et al., 2019;
344 Chung, 2011; Halayko and Ghavami, 2009; Mattos et al., 2002). Remarkably, these
345 molecules were significantly upregulated in severe-fatal in comparison to mild and
346 severe-survival patients (Fig. 4D), the former of which also exhibited a persistent elevation of
347 type I interferon responses (Fig. 4A). Together, the data generated here indicate that
348 autoinflammation may amplify disease in very severe cases of COVID-19.

349 Patients will receive better and precision therapy if we are able to identify molecular
350 biomarkers associated with prognosis at the beginning of disease presentation. For example,
351 a 21-gene expression assay, which can predict clinical outcome, is used in the case of breast
352 cancer (Sparano et al., 2018). To date, however, almost no biomarkers have been used to
353 accurately predict prognosis in the case of emerging infectious diseases (Wynants et al.,

354 2020). In this study, some of molecules identified at the beginning phase of COVID-19 were
355 significantly correlated to both classical blood and biochemical parameters, and more
356 importantly to disease severity. Based on our previous work (Shi et al., 2010; Su et al., 2014a;
357 Zhang et al., 2015), we established classification models based on each of four data types:
358 exRNAs, mRNA, proteins, and biochemical parameters. Notably, COVID-19 clinical outcomes
359 could be accurately predicted using just one or two biomarkers in each data type. In addition,
360 these biomarkers may have biological functions directly relevant to COVID-19
361 pathophysiology. For example, biomarkers *let-7* family from exRNAs, OLAH and CD3E from
362 mRNAs, and C4A and C4B from proteomes concordantly revealed the importance of T-cell
363 activation and the suppression inflammatory responses. However, because of the relatively
364 small patient sample size utilized here, it is clear that more work is needed to confirm the
365 reliability and practicality these biomarkers.

366 In sum, we have identified a large number of molecules associated with COVID-19
367 pathophysiology, some of which may also be effective predictive biomarkers of clinical
368 outcome at the onset of disease. In addition, these data suggest that both distinct immune
369 responses and multi-organ damage have a major impact on COVID-19 severity and disease
370 prognosis.

371

372 **Materials and Methods**

373 **Study design and patient cohort**

374 According to arrangements made by the Chinese Government, all adult patients in Shanghai
375 diagnosed with COVID-19 were admitted to the Shanghai Public Health Clinical Center. We
376 enrolled 66 COVID-19 patients who were treated at the Shanghai Public Health Clinical
377 Center between January 31st and April 7th, 2020. Based on clinical signs and the need for
378 oxygen, these patients were divided into two groups: (i) mild (50/66, 75.8%) – with clinical
379 signs of pneumonia but without oxygen support, and (ii) severe (16/66, 24.2%) – with oxygen
380 support using non-invasive ventilation, tracheal tube, tracheotomy assist ventilation or
381 extracorporeal membrane oxygenation (ECMO) (Fig. 1A and Table S1). All human samples
382 included in the present study were obtained after approval of the research by the Shanghai
383 Public Health Clinical Center Ethics Committee (YJ-2020-S018-02), together with the written
384 informed consent from each patient.

385 **Sample collection and processing**

386 A total of 277 blood samples, comprising 1-2 mL each, were collected by professional
387 healthcare workers over a 5-week period, with one to five sampling time points from each
388 patient. In addition, 17 blood samples were collected from 17 uninfected volunteers and
389 utilized as healthy controls. Samples were transported to the research laboratory within two
390 hours of collection. For RNA extraction, 200 μ L of whole blood was mixed with 1 mL QRIzol
391 reagent (Qiagen), followed by 15 min incubation at room temperature and subsequent
392 freezing at -80°C before total RNA extraction. The remaining whole blood samples (800-1800
393 μ L) were processed immediately to separate plasma and subsequently stored at -80°C until
394 use.

395 All clinical data were recorded by the clinicians. COVID-19 loads were determined by
396 quantitative real-time RT-PCR using the Takara One Step PrimeScript RT-PCR kit (Takara
397 RR064A) as previously described (Wu et al., 2020a). Quantitative viral load tests were
398 performed using the BioDigital General dPCR kit (Jiangsu Saint Genomics, Cat no.
399 CSJ-3-0018).

400 **RNA and exRNA extraction and library construction**

401 Total RNA from whole blood samples was extracted using the RNeasy Plus Universal Mini Kit
402 (Qiagen) following the manufacturer's instructions. The quantity and quality of RNA solution
403 were assessed using a Qubit Flex fluorometer (Invitrogen) and an Agilent Bioanalyzer (Agilent
404 Technologies) before library construction and sequencing. RNA library construction was
405 performed as described using the VAHTS Universal V6 RNA-seq Library Prep Kit for Illumina
406 (Vazyme, China). Ribosomal, globin and RN7S RNAs were depleted using specially designed
407 probes (Vazyme, China).

408 Plasma samples were divided into aliquots and used for extracellular RNA (exRNA)
409 extraction and library construction, protein extraction and metabolomic analyses. For exRNA
410 library preparation, total RNA including exRNA was extracted using the miRNeasy
411 Serum/Plasma Advanced Kit (Qiagen). The exRNA library was prepared using the NEXTflex
412 Small RNA-seq Kit v3 (PerkinElmer). RNA quantity and quality were determined as
413 mentioned above. After final library quantification using a Qubit Flex fluorometer (Invitrogen)
414 and quality control using the Bioptic Qsep100 to confirm the expected size distributions, all

415 libraries (RNA and exRNA) were pair-end (150-bp reads) sequenced on the Illumina

416 NovaSeq6000 platform (Illumina).

417 **RNA-seq data analysis**

418 ***Data processing and filtering criteria***

419 Preliminary processing of raw reads was performed using FASTP v0.19.6 to remove adapter

420 sequences and obtain trimmed reads (Chen et al., 2018). The sequence

421 AGATCGGAAGAGCACACGTCTGAACTCCAGTCA was used as the R1 adapter sequence

422 while AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT was used as the R2 adapter

423 sequence. HISAT2 v2.1 (Pertea et al., 2016) was used for read alignment to the human

424 genome, build 38. Samtools v1.3.1 was used to generate intermediate result files for quality

425 assessment of the aligned reads by BamQC v2.0.0 (<https://github.com/s-andrews/BamQC>)

426 and insert size distribution analysis. The assembly of aligned reads and assessment of

427 expression levels were processed through StringTie v1.3.4. Gene counts were determined

428 with preDE.py (<http://ccb.jhu.edu/software/stringtie/>) based on results derived from Ballgown

429 (<https://github.com/alyssafrazee/ballgown>). Ensembl transcript annotation (version:

430 Homo_sapiens.GRCh38.93.gtf) with 58,395 genes was used.

431 A QC analysis and library filtering were performed before downstream biological

432 analysis. Libraries that passed the following criteria were retained: (i) more than five million

433 reads; (ii) more than 90% of reads aligned to the human reference genome; (iii) over 10,000

434 genes were expressed (a gene with FPKM>0.5 was identified as an expressed gene). In

435 addition, to monitor data quality across batches, libraries of some healthy control samples

436 were constructed and sequenced 2-3 times. The average expression profile of the multiple
437 libraries from each healthy control sample were calculated for follow-up analyses.

438 ***Immunoassay***

439 Immune repertoires were extracted with MiXCR, a software tool that extracts T-cell receptor
440 (TCR) and immunoglobulin (IG) repertoires from RNA-seq data (Bolotin et al., 2017; Bolotin et
441 al., 2015). The number of clonotypes was then calculated using VDJtools, using the output
442 from MiXCR (Shugay et al., 2015).

443 ***Differentially expressed genes (DEGs)***

444 To identify DEGs, a Student's t-test was applied to the expression matrix. Genes with p-values
445 less than 0.05 as well as a fold change >2 or $<1/2$ were labeled as up-regulated and
446 down-regulated genes, respectively (Su et al., 2014b). This straightforward approach of
447 combining a fold change cut-off with a non-stringent p-value threshold has been
448 demonstrated to yield reproducible and robust lists of DEGs for both microarray and RNA-seq
449 based gene-expression analyses (Shi et al., 2006; Su et al., 2014b).

450 ***Functional and cell type enrichment analyses***

451 Functional analyses were conducted based on genes differentially expressed between
452 several subgroups of COVID-19 patients compared with healthy control samples. GSEA
453 (Gene Set Enrichment Analyses) was performed to identify significantly enriched functional
454 classes of gene sets correlated with blood transcription modules (BTM) described by Li et al.
455 (2014), KEGG pathways, and Gene Ontology (GO) terms. A default FDR (false discovery rate)

456 value of $q < 0.25$ was considered statistically significant. The Normalized Enrichment Score
457 (NES) of significant immune modules from BTMs was used to denote enrichment levels.

458 The fraction of the cell subsets was calculated using the enrichment-score based
459 algorithm xCell from the RNA-seq data (Aran et al., 2017). Briefly, the expression profile
460 (FPKM) of all 230 samples was employed as raw signatures. The R package immunedeconv
461 was applied to obtain enrichment scores of 35 immune cell types, estimating immune cell
462 fractions including T cell, monocyte and neutrophil by summation of the scores in each
463 sample (Sturm et al., 2019).

464 **exRNA-seq data analysis**

465 ***Alignment, quantification and quality control***

466 Libraries were sequenced in two batches, with an average sequencing depth of 15.7M raw
467 reads per library. All FASTQ files were delivered to the ExceRpt small RNA sequencing data
468 analysis pipeline (docker v4.6.3) (Rozowsky et al., 2019). Default parameters were used with
469 exception of: (i) the sequence TGG AATTCTCGGGTGCCAAGG was given as the 3'adapter
470 sequence, ignoring the adapter sequences guessed by the pipeline; (ii) the random barcode
471 length was set to 4; (iii) the priority of the reference libraries during read assignment was set
472 to miRNA > piRNA > tRNA > GENCODE > circRNA (Godoy et al., 2018). Pre-compiled
473 genome and transcriptome indices of human genome, build 38 were used. The raw read
474 count matrix was then normalized using count per million (CPM).

475 A QC analysis was performed prior to biological analysis by removing (i) libraries with

476 low sequencing depths (<1M raw reads); (ii) libraries with mapping ratio lower than 50%, and
477 (iii) libraries with low transcript-genome ratios. To minimize the impact of noise due to low
478 expression levels, only 769 miRNAs with at least 1 count per million in no less than 10% of the
479 total number of samples were included in the final analysis.

480 ***Differentially expressed exRNAs***

481 To identify differentially expressed exRNAs, Student's t-tests were applied to the normalized
482 expression matrix. exRNAs with p-values less than 0.05, as well as fold change > 2 or < 1/2,
483 were labeled as up-regulated and down-regulated exRNAs, respectively, in a similar manner
484 to the RNA-seq data.

485 ***Tissue-damage related miRNAs***

486 exRNAs reported to be associated with tissue damage were collected from publications (Atif
487 and Hicks, 2019; Godwin et al., 2010; Wang et al., 2010; Wang et al., 2009; Zhou et al.,
488 2016)(Table S8). Fisher's exact test was used to determine whether the proportions of
489 differentially expressed (DE) exRNAs in tissue-damage related exRNAs were significantly
490 higher than the proportions of DE exRNAs in the entire data set of 769 miRNAs.

491 **Proteome analysis**

492 ***Plasma Protein extraction and trypsin digestion***

493 Plasma samples used for protein extraction were first removed the top 14 highest abundance
494 plasma proteins using an immunodepleting kit (Thermo Fisher) according to the
495 manufacturer's instructions, and then inactivated at 85°C for 10 mins. The depleted plasma

496 was digested by trypsin at an enzyme to protein mass ratio of 1:25 overnight at 37°C, and the
497 peptides were then extracted and dried (SpeedVac, Eppendorf).

498 ***LC-MS/MS Acquisition of Plasma Samples***

499 Samples were measured using LC-MS instrumentation consisting of an EASY- nLC 1200
500 ultra-high-pressure system (Thermo Fisher Scientific) coupled via a nano-electrospray ion
501 source (Thermo Fisher Scientific) to a Fusion Lumos Orbitrap (Thermo Fisher Scientific). The
502 peptides were dissolved with 12 µl loading buffer (0.1% formic acid in water), and 5 µl was
503 loaded onto a 100 µm I.D. × 2.5 cm, C18 trap column at a maximum pressure 280 bar with 14
504 µl solvent A (0.1% formic acid in water). Peptides were separated on 150 µm I.D. × 15 cm
505 column (C18, 1.9µm, 120 Å, Dr. Maisch GmbH) with a linear 15–30% Mobile Phase B (ACN
506 and 0.1% formic acid) at 600 nl/min for 75 mins. The MS analysis was performed in a
507 data-independent manner. The DIA method consisted of MS1 scan from 300-1400 m/z at 60k
508 resolution (AGC target 4e5 or 50 ms). Then 30 DIA segments were acquired at 15k resolution
509 with an AGC target 5e4 or 22 ms for maximal injection time. The setting “inject ions for all
510 available parallelizable time” was enabled. HCD fragmentation was set to normalized collision
511 energy of 30%. The spectra were recorded in profile mode. The default charge state for the
512 MS2 was set to 3.

513 ***Peptide identification and protein quantification***

514 All data were processed using Firmiana (Feng et al., 2017). The DDA data were search
515 against UniProt human protein database (updated on 2019.12.17, 20406 entries) using
516 FragPipe (v12.1) with MSFragger (2.2) (Kong et al., 2017). The mass tolerances were 20 ppm

517 for precursor and 50 mmu for product ions. Up to two missed cleavages were allowed. The
518 search engine set cysteine carbamidomethylation as a fixed modification and N-acetylation
519 and oxidation of methionine as variable modifications. Precursor ion score charges were
520 limited to +2, +3, and +4. The data were also searched against a decoy database so that
521 protein identifications were accepted at a false discovery rate (FDR) of 1%. The results of
522 DDA data were combined into spectra libraries using SpectraST software. A total of 327
523 libraries were used as reference spectra libraries.

524 DIA data was analyzed using DIANN (v1.7.0) (Demichev et al., 2020). The default
525 settings were used for DIA-NN (Precursor FDR: 5%, Log lev: 1, Mass accuracy: 20 ppm, MS1
526 accuracy: 10 ppm, Scan window: 30, Implicit protein group: genes, Quantification strategy:
527 robust LC (high accuracy). Quantification of identified peptides was calculated as the average
528 of chromatographic fragment ion peak areas across all reference spectra libraries. Label-free
529 protein quantifications were calculated using a label-free, intensity-based absolute
530 quantification (iBAQ) approach (Zhang et al., 2012). We calculated the peak area values as
531 parts of corresponding proteins. The fraction of total (FOT) was used to represent the
532 normalized abundance of a particular protein across samples. FOT was defined as a protein's
533 iBAQ divided by the total iBAQ of all identified proteins within a sample. The FOT values were
534 multiplied by 10^5 for the ease of presentation and missing values were imputed with 10^{-5} .

535 **Metabolome analysis**

536 ***NMR spectroscopy***

537 The plasma samples used for NMR analysis were first treated with 56°C for 30 min. Our
538 subsequent quantitative measurements of samples from healthy controls showed that such
539 treatments caused no differences to the quantification results.

540 NMR analysis was conducted on a 600 MHz NMR spectrometer (Bruker Biospin) as
541 reported previously (Jimenez et al., 2018) with some minor modifications. In brief, 320µL of
542 each plasma sample was mixed with 320µL of a phosphate buffer (0.085 M containing 10%
543 D₂O) with composition described previously (Jiang et al., 2012), and 600µL mixture was
544 transferred into a 5mm NMR tube for NMR analysis. 152 parameters of the plasma were then
545 quantified using a server-based software package (Bruker Biospin), including 112 parameters
546 for lipoproteins (including main fractions, subclasses and compositional components therein),
547 two acute-phase glycoproteins together with 41 small metabolites (such as amino acids,
548 ketone bodies, glucose, carboxylic acids, ethanol). We also quantified six ratio-parameters for
549 saturated, unsaturated, monounsaturated and polyunsaturated fatty acids from the
550 diffusion-edited spectra (Xu et al., 2012). We further calculated 187 more ratio-parameters
551 (such as the cholesterol-to-triglyceride ratio, percentage of triglycerides and cholesterol in
552 total lipids) from the quantitative data for lipoproteins. A total of 348 quantitative parameters
553 obtained were collectively employed to define the metabolomic phenotypes of each of the
554 human plasma samples.

555 **Development of prognostic models**

556 ***Model development***

557 Four data sets representing the (i) clinical tests, (ii) exRNA-seq, (iii) mRNA-seq, and (iv)
558 proteomics quantification analysis were used to develop prognostic models for the prediction
559 of patient outcomes (i.e. good or poor). Patients with a “good” outcome included those with
560 mild or severe syndrome but who were discharged after treatment; while patients with “poor”
561 outcomes included those who died or remained in ICU for more than two months.

562 Prognostic models were developed and validated using a two-layer validation strategy
563 (Fig. S5A) to prevent information leaking from the training set to the validation set¹³. Briefly,
564 patients were first divided into training and validation sets with equal size based on outcome
565 and admission date. The training set was then used to select variables and train prognostic
566 models using multiple machine learning algorithms, including nearest mean classification
567 (NMC), k-nearest neighbors (KNN), support vector machine (SVM), and random forest (RF)
568 through an internal-layer of 50 runs of five-fold cross-validation process to resist overfitting.
569 Next, a final model was built using the whole training set with the best performing machine
570 learning algorithm as defined above. The final model was further validated using the
571 validation set as an external-layer evaluation. Model performance was assessed in terms of
572 the Matthews correlation coefficient (MCC), AUC, accuracy, sensitivity, specificity, positive
573 predictive value (PPV) and negative predictive value (NPV).

574 Prognostic biomarkers were identified based on the frequency of variables selected by
575 machine learning algorithms. Because the sample size was relatively small compared to the
576 large number of variables, it was difficult to identify stable biomarkers as indicated by the low
577 frequencies of the variables used in the prognostic models¹³ (Figs. S5A and S5B). To detect

578 more robust prognostic biomarkers, 50 runs of five-fold cross-validation process were
579 therefore applied to the whole data set. The variables used by the best performing machine
580 learning algorithm were identified as prognostic biomarkers for each data set.

581 ***Learning curve model comparison***

582 Learning curve model comparison (LCMC) was performed using Predictive Modeling Review
583 as available in JMP Genomics 10
584 (https://www.jmp.com/en_us/software/genomics-data-analysis-software.html). LCMC reveals
585 the effects of sample size on the accuracy and variability of the predictive models using 10
586 runs of 4-fold cross-validation.

587 We performed LCMC with prognosis (good or poor) as target variables, and the clinical
588 variables, exRNA, mRNA, or proteomics measurements as predictors. Fig. S5C shows each
589 individual (RMSE) and (AUC) learning curve and the average for each of the eight partition
590 tree models for clinical endpoints, as well as exRNA using K-fold cross validation. The LCMC
591 suggested that with up to 15 samples, eight partition tree models reached AUC as 1 for
592 clinical variables. However, more than 23 and 30 samples were needed for one and three
593 models, respectively, to reach AUC of 1 for exRNA-seq data. The variability of RMSE and
594 AUC for the proteomic and mRNA-seq data (not shown) were between that observed for
595 clinical variables and the exRNA data.

596 **Statistical Analyses**

597 Univariate statistical analysis was performed using student's t-test, Mann-Whitney U tests or
598 ANOVA tests to compare continuous variables. Chi-square tests and Fisher's exact tests

599 were used for the comparison of categorical variables. p -values were adjusted using
600 Bonferroni correction or the Benjamini and Hochbery False Discovery Rate (FDR) in multiple
601 comparisons, with $p < 0.05$ considered to be statistically significant. Principal components
602 analysis (PCA) was conducted with univariance scaling, with the scores plot showing a
603 distribution of metabolomic phenotypes for healthy participants and patients with moderate or
604 severe COVID-19 (and upon discharge). Correlations were tested using Pearson correlation
605 coefficients. Locally Weighted Linear Regression (Loess) was used for visualizing the time
606 series data. All analyses were performed using appropriate R packages (version 3.5.1).
607

608 **Acknowledgements**

609 We acknowledge the support from Volvo Car Corporation. This study was supported by the
610 National Natural Science Foundation of China (grants 81861138003, 31930001, 32041004
611 and 81672057) and the Special National Project on investigation of basic resources of China
612 (grant 2019FY101400), and Shanghai Municipal Science and Technology Major Project
613 (Grant No. 2017SHZDZX01). E.C.H. is supported by an ARC Australian Laureate Fellowship
614 (FL170100022).

615

616 **Author contributions**

617 Y.-Z.Z. conceived and designed the study. Y.-Z.Z., T.-Y.Z., C.D., L.M.S., H.R.T., Y.L., Z.Y.
618 and L.J. designed and developed methodology. T.-Y.Z., Y.L. and Z.-G.S. performed the
619 clinical work and sample collection. Y.-M.C, Y.-T.Z., Y.-Z.W., Q.-X.H., S.-Y.S., Z.-G.S.,

620 F.-H.D., Y.-P.A., Q.-S.C. and Q.-W. L. performed the experiments. Y.Y., Y.-Z.W., Q.-X.H.,
621 Y.-M.C., F.Q, L.S., Z.-Y.C., J.-C.Y., Z.-Q.S., J.-W.F. and P.-C.L. analysed the data. Y.-Z.Z.,
622 C.D., F.Q, L.S., Y.Y., Y.-Z.W., Y.-M.C., Q.-X.H., L.M.S., H.R.T. and E.C.H. wrote the paper
623 with input from all authors.

624

625 **Conflict of interest**

626 The authors declare no competing interests.

627

628 **Data Availability**

629 The datasets produced in this study are available in the following databases:

630 ● RNA-Seq and exRNA-Seq Data: NODE [OEP000868](#)

631 (<http://www.biosino.org/node/project/detail/OEP000868>)

632 ● Raw mass spectrometry data: iProX [IPX 0002186001](#)

633 (<https://www.iprox.org/page/subproject.html?id=IPX0002186001>)

634

635 **References**

- 636 Akiyama, M., Zeisbrich, M., Ibrahim, N., Ohtsuki, S., Berry, G.J., Hwang, P.H., *et al.* (2019).
637 Neutrophil extracellular traps induce tissue-invasive monocytes in granulomatosis with
638 polyangiitis. *Front Immunol* 13 November DOI: 103389/fimmu201902617.
- 639 Alonso, D.O., Iglesias, A., Coelho, R., Periolo, N., Bruno, A., Córdoba, M.T., *et al.* (2019).
640 Epidemiological description, case-fatality rate, and trends of Hantavirus Pulmonary
641 Syndrome: 9 years of surveillance in Argentina. *J Med Virol* 91: 1173-1181.
- 642 Aran, D., Hu, Z., and Butte, A.J. (2017). xCell: digitally portraying the tissue cellular
643 heterogeneity landscape. *Genome Biol* 18: 220.
- 644 Atif, H., and Hicks, S.D. (2019). A Review of MicroRNA Biomarkers in Traumatic Brain Injury.
645 *J Exp Neurosci* 13: 1179069519832286.
- 646 Baig, A.M. (2020). Neurological manifestations in COVID-19 caused by SARS-CoV-2. *CNS*
647 *Neurosci Ther* 26: 499.
- 648 Baig, A.M., Khaleeq, A., Ali, U., and Syeda, H. (2020). Evidence of the COVID-19 Virus
649 Targeting the CNS: Tissue Distribution, Host–Virus Interaction, and Proposed
650 Neurotropic Mechanisms. *ACS Chem Neurosci* 11: 995-998.
- 651 Barton, L.M., Duval, E.J., Stroberg, E., Ghosh, S., and Mukhopadhyay, S. (2020). COVID-19
652 Autopsies, Oklahoma, USA. *Am J Clin Pathol*, 10 April, DOI:
653 <https://doi.org/101093/ajcp/aqaa062>.
- 654 Baseler, L., Chertow, D.S., Johnson, K.M., Feldmann, H., and Morens, D.M. (2017). The
655 pathogenesis of Ebola virus disease. *Annu Rev Pathol* 12: 387-418.

- 656 Bermingham, A., Chand, M., Brown, C., Aarons, E., Tong, C., Langrish, C., *et al.* (2012).
657 Severe respiratory illness caused by a novel coronavirus, in a patient transferred to
658 the United Kingdom from the Middle East, September 2012. *Euro Surveill* 17: 20290.
- 659 Blanco-Melo, D., Nilsson-Payant, B.E., Liu, W.-C., Uhl, S., Hoagland, D., Møller, R., *et al.*
660 (2020). Imbalanced host response to SARS-CoV-2 drives development of COVID-19.
661 *Cell*, DOI: 101016/jcell202004026.
- 662 Bohmwald, K., Gálvez, N.M., Canedo-Marroquín, G., Pizarro-Ortega, M.S., Andrade-Parra,
663 C., Gómez-Santander, F., and Kalergis, A.M. (2019). Contribution of cytokines to
664 tissue damage during human respiratory syncytial virus infection. *Front Immunol* 18
665 March DOI: 103389/fimmu201900452.
- 666 Bolotin, D.A., Poslavsky, S., Davydov, A.N., Frenkel, F.E., Fanchi, L., Zolotareva, O.I., *et al.*
667 (2017). Antigen receptor repertoire profiling from RNA-seq data. *Nat Biotechnol* 35:
668 908-911.
- 669 Bolotin, D.A., Poslavsky, S., Mitrophanov, I., Shugay, M., Mamedov, I.Z., Putintseva, E.V.,
670 and Chudakov, D.M. (2015). MiXCR: software for comprehensive adaptive immunity
671 profiling. *Nat Methods* 12: 380-381.
- 672 Cai, Q., Huang, D., Yu, H., Zhu, Z., Xia, Z., Su, Y., *et al.* (2020). Characteristics of Liver Tests
673 in COVID-19 Patients. *J Hepatol* 13 April DOI: <https://doi.org/101016/jjhep202004006>.
- 674 Cao, X. (2020). COVID-19: immunopathology and its implications for therapy. *Nat Rev*
675 *Immunol* 09 April DOI: <https://doi.org/101038/s41577-020-0308-3>.

- 676 Chai, X., Hu, L., Zhang, Y., Han, W., Lu, Z., Ke, A., *et al.* (2020). Specific ACE2 expression in
677 cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv DOI:
678 <https://doi.org/10.1101/20200203931766>.
- 679 Channappanavar, R., Zhao, J., and Perlman, S. (2014). T cell-mediated immune response to
680 respiratory coronaviruses. *Immunol Res* 59: 118-128.
- 681 Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., *et al.* (2020a). Epidemiological and
682 clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan,
683 China: a descriptive study. *The Lancet* 30 January DOI:
684 [https://doi.org/10.1016/S0140-6736\(20\)30211-7](https://doi.org/10.1016/S0140-6736(20)30211-7).
- 685 Chen, R., Yu, J., Wang, K., Chen, Z., Wen, C., and Xu, Z. (2020b). The spatial and cell-type
686 distribution of SARS-CoV-2 receptor ACE2 in human and mouse brain. bioRxiv DOI:
687 <https://doi.org/10.1101/20200407030650>.
- 688 Chen, S., Zhou, Y., Chen, Y., and Gu, J. (2018). fastp: an ultra-fast all-in-one FASTQ
689 preprocessor. *Bioinformatics* 34: i884-i890.
- 690 Cheng, Y., Ma, X.L., Wei, Y.Q., and Wei, X.W. (2019). Potential roles and targeted therapy of
691 the CXCLs/CXCR2 axis in cancer and inflammatory diseases. *Biochim Biophys Acta*
692 *Rev Cancer* 1871: 289-312.
- 693 Chung, K.F. (2011). p38 mitogen-activated protein kinase pathways in asthma and COPD.
694 *Chest* 139: 1470-1479.

- 695 Cicchese, J.M., Evans, S., Hult, C., Joslyn, L.R., Wessler, T., Millar, J.A., *et al.* (2018).
696 Dynamic balance of pro-and anti-inflammatory signals controls disease and limits
697 pathology. *Immunol Rev* 285: 147-167.
- 698 Cui, J., Li, F., and Shi, Z.-L. (2019). Origin and evolution of pathogenic coronaviruses. *Nat*
699 *Rev Microbiol* 17: 181-192.
- 700 Dada, L.A., Chandel, N.S., Ridge, K.M., Pedemonte, C., Bertorello, A.M., and Sznajder, J.I.
701 (2003). Hypoxia-induced endocytosis of Na, K-ATPase in alveolar epithelial cells is
702 mediated by mitochondrial reactive oxygen species and PKC- ζ . *J Clin Invest* 111:
703 1057-1064.
- 704 Demichev, V., Messner, C.B., Vernardis, S.I., Lilley, K.S., and Ralser, M. (2020). DIA-NN:
705 neural networks and interference correction enable deep proteome coverage in high
706 throughput. *Nat Methods* 17: 41-44.
- 707 Du, X., Yu, X., Li, Q., Li, X., Qin, T., Luo, Q., *et al.* (2020). Duration for Carrying SARS-CoV-2
708 in COVID-19 Patients. *J Infect Dis.*
- 709 Fan, C., Li, K., Ding, Y., Lu, W.L., and Wang, J. (2020). ACE2 expression in kidney and testis
710 may cause kidney and testis damage after 2019-nCoV infection. *MedRxiv DOI:*
711 <https://doi.org/10.1101/2020021220022418>.
- 712 Feng, J., Ding, C., Qiu, N., Ni, X., Zhan, D., Liu, W., *et al.* (2017). Firmiana: towards a
713 one-stop proteomic cloud platform for data processing and analysis. *Nat Biotechnol* 35:
714 409-412.

- 715 Gautam, N., Olofsson, A.M., Herwald, H., Iversen, L.F., Lundgren-Åkerlund, E., Hedqvist, P.,
716 *et al.* (2001). Heparin-binding protein (HBP/CAP37): a missing link in
717 neutrophil-evoked alteration of vascular permeability. *Nat Med* 7: 1123-1127.
- 718 Godoy, P.M., Bhakta, N.R., Barczak, A.J., Cakmak, H., Fisher, S., MacKenzie, T.C., *et al.*
719 (2018). Large Differences in Small RNA Composition Between Human Biofluids. *Cell*
720 *Rep* 25: 1346-1358.
- 721 Godwin, J.G., Ge, X., Stephan, K., Jurisch, A., Tullius, S.G., and Iacomini, J. (2010).
722 Identification of a microRNA signature of renal ischemia reperfusion injury. *Proc Natl*
723 *Acad Sci U S A* 107: 14339-14344.
- 724 Guan, W.-j., Ni, Z.-y., Hu, Y., Liang, W.-h., Ou, C.-q., He, J.-x., *et al.* (2020). Clinical
725 characteristics of coronavirus disease 2019 in China. *N Engl J Med* 28 February DOI:
726 101056/NEJMoa2002032.
- 727 Halayko, A.J., and Ghavami, S. (2009). S100A8/A9: a mediator of severe asthma
728 pathogenesis and morbidity? *Can J Physiol Pharmacol* 87: 743-755.
- 729 Hamming, I., Timens, W., Bulthuis, M., Lely, A., Navis, G., and van Goor, H. (2004). Tissue
730 distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step
731 in understanding SARS pathogenesis. *J Pathol* 203: 631-637.
- 732 Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., *et al.* (2020). Clinical features of
733 patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet* 395:
734 497-506.

- 735 Jiang, F., Yang, J., Zhang, Y., Dong, M., Wang, S., Zhang, Q., *et al.* (2014).
736 Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets. *Nat*
737 *Rev Cardiol* 11: 413-426.
- 738 Jiang, L., Huang, J., Wang, Y., and Tang, H. (2012). Eliminating the dication-induced
739 intersample chemical-shift variations for NMR-based biofluid metabonomic analysis.
740 *Analyst* 137: 4209-4219.
- 741 Jimenez, B., Holmes, E., Heude, C., Tolson, R.F., Harvey, N., Lodge, S.L., *et al.* (2018).
742 Quantitative Lipoprotein Subclass and Low Molecular Weight Metabolite Analysis in
743 Human Serum and Plasma by (1)H NMR Spectroscopy in a Multilaboratory Trial. *Anal*
744 *Chem* 90: 11962-11971.
- 745 Kong, A.T., Leprevost, F.V., Avtonomov, D.M., Mellacheruvu, D., and Nesvizhskii, A.I. (2017).
746 MSFragger: ultrafast and comprehensive peptide identification in mass
747 spectrometry–based proteomics. *Nat Methods* 14: 513.
- 748 Kruger, P., Saffarzadeh, M., Weber, A.N., Rieber, N., Radsak, M., von Bernuth, H., *et al.*
749 (2015). Neutrophils: between host defence, immune modulation, and tissue injury.
750 *PLoS Pathog* 11: e1004651.
- 751 Ksiazek, T.G., Erdman, D., Goldsmith, C.S., Zaki, S.R., Peret, T., Emery, S., *et al.* (2003). A
752 novel coronavirus associated with severe acute respiratory syndrome. *N Engl J Med*
753 348: 1953-1966.

- 754 Li, S., Rouphael, N., Duraisingham, S., Romero-Steiner, S., Presnell, S., Davis, C., *et al.*
755 (2014). Molecular signatures of antibody responses derived from a systems biology
756 study of five human vaccines. *Nat Immunol* 15: 195-204.
- 757 Lin, L., Lu, L., Cao, W., and Li, T. (2020). Hypothesis for potential pathogenesis of
758 SARS-CoV-2 infection—a review of immune changes in patients with viral
759 pneumonia. *Emerg Microbes Infect*: 1-14.
- 760 Mao, L., Wang, M., Chen, S., He, Q., Chang, J., Hong, C., *et al.* (2020). Neurologic
761 Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan,
762 China. *JAMA Neurol* 10 April DOI: 10.1001/jamaneurol.2020.1127.
- 763 Masters, P., and Perlman, S. (2013). “Coronaviridae”, *Fields virology*, Vol 1 (Lippincott
764 Williams & Wilkins, Philadelphia, PA).
- 765 Mattos, W., Lim, S., Russell, R., Jatakanon, A., Chung, K.F., and Barnes, P.J. (2002). Matrix
766 Metalloproteinase-9 Expression in Asthma: Effect of Asthma Severity, Allergen
767 Challenge, and Inhaled Corticosteroids. *Chest* 122: 1543-1552.
- 768 Murphy, K., and Weaver, C. (2016). *Janeway's immunobiology* 9th edition (Garland Science).
- 769 Newton, A.H., Cardani, A., and Braciale, T.J. (2016). The host immune response in
770 respiratory virus infection: balancing virus clearance and immunopathology. *Semin*
771 *Immunopathol* 38: 471-482.
- 772 Oschatz, C., Maas, C., Lecher, B., Jansen, T., Björkqvist, J., Tradler, T., *et al.* (2011). Mast
773 cells increase vascular permeability by heparin-initiated bradykinin formation in vivo.
774 *Immunity* 34: 258-268.

- 775 Pertea, M., Kim, D., Pertea, G.M., Leek, J.T., and Salzberg, S.L. (2016). Transcript-level
776 expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown. Nat
777 Protoc 11: 1650-1667.
- 778 Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y., *et al.* (2020). Dysregulation of immune
779 response in patients with COVID-19 in Wuhan, China. Clin Infect Dis 12 Mar DOI:
780 101093/cid/ciaa248.
- 781 Rozowsky, J., Kitchen, R.R., Park, J.J., Galeev, T.R., Diao, J., Warrell, J., *et al.* (2019).
782 exceRpt: A Comprehensive Analytic Platform for Extracellular RNA Profiling. Cell Syst
783 8: 352-357.e353.
- 784 Ruibal, P., Oestereich, L., Ludtke, A., Becker-Ziaja, B., Wozniak, D.M., Kerber, R., *et al.*
785 (2016). Unique human immune signature of Ebola virus disease in Guinea. Nature
786 533: 100-104.
- 787 Shi, L., Campbell, G., Jones, W.D., Campagne, F., Wen, Z., Walker, S.J., *et al.* (2010). The
788 MicroArray Quality Control (MAQC)-II study of common practices for the development
789 and validation of microarray-based predictive models. Nat Biotech 28: 827.
- 790 Shi, L., Reid, L.H., Jones, W.D., Shippy, R., Warrington, J.A., Baker, S.C., *et al.* (2006). The
791 MicroArray Quality Control (MAQC) project shows inter- and intraplatform
792 reproducibility of gene expression measurements. Nat Biotechnol 24: 1151-1161.
- 793 Shi, Y., Tan, M., Chen, X., Liu, Y., Huang, J., Ou, J., and Deng, X. (2020).
794 Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou,
795 China. medRxiv DOI: 101101/2020031220034736: 2020.2003.2012.20034736.

- 796 Shugay, M., Bagaev, D.V., Turchaninova, M.A., Bolotin, D.A., Britanova, O.V., Putintseva,
797 E.V., *et al.* (2015). VDJtools: Unifying Post-analysis of T Cell Receptor Repertoires.
798 PLoS Comput Biol 11: e1004503.
- 799 Sparano, J.A., Gray, R.J., Makower, D.F., Pritchard, K.I., Albain, K.S., Hayes, D.F., *et al.*
800 (2018). Adjuvant chemotherapy guided by a 21-gene expression assay in breast
801 cancer. N Engl J Med 379: 111-121.
- 802 Sridhar, S., Begom, S., Bermingham, A., Hoschler, K., Adamson, W., Carman, W., *et al.*
803 (2013). Cellular immune correlates of protection against symptomatic pandemic
804 influenza. Nat Med 19: 1305-1312.
- 805 Sturm, G., Finotello, F., Petitprez, F., Zhang, J.D., Baumbach, J., Fridman, W.H., *et al.* (2019).
806 Comprehensive evaluation of transcriptome-based cell-type quantification methods for
807 immuno-oncology. Bioinformatics 35: i436-i445.
- 808 Su, Z., Fang, H., Hong, H., Shi, L., Zhang, W., Zhang, W., *et al.* (2014a). An investigation of
809 biomarkers derived from legacy microarray data for their utility in the RNA-seq era.
810 Genome Biol 15: 523.
- 811 Su, Z., Łabaj, P.P., Li, S., Thierry-Mieg, J., Thierry-Mieg, D., Shi, W., *et al.* (2014b). A
812 comprehensive assessment of RNA-seq accuracy, reproducibility and information
813 content by the Sequencing Quality Control Consortium. Nat Biotechnol 32: 903-914.
- 814 Tian, S., Hu, W., Niu, L., Liu, H., Xu, H., and Xiao, S.-Y. (2020). Pulmonary pathology of early
815 phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung
816 cancer. J Thorac Oncol 27 February DOI: <https://doi.org/10.1016/j.jtho.2020.02.010>.

- 817 Vadász, I., and Sznajder, J.I. (2017). Gas exchange disturbances regulate alveolar fluid
818 clearance during acute lung injury. *Front Immunol* 8: 757.
- 819 van de Sandt, C.E., Kreijtz, J.H., de Mutsert, G., Geelhoed-Mieras, M.M., Hillaire, M.L.,
820 Vogelzang-van Trierum, S.E., *et al.* (2014). Human cytotoxic T lymphocytes directed
821 to seasonal influenza A viruses cross-react with the newly emerging H7N9 virus. *J*
822 *Viro* 88: 1684-1693.
- 823 Wadman, M., Couzin-Frankel, J., Kaiser, J., and Maticic, C. (2020). How does coronavirus
824 kill? Clinicians trace a ferocious rampage through the body, from brain to toes.
825 *Science* 17 April
826 [https://www.sciencemag.org/news/2020/04/how-does-coronavirus-kill-clinicians-trace-f](https://www.sciencemag.org/news/2020/04/how-does-coronavirus-kill-clinicians-trace-ferocious-rampage-through-body-brain-toes)
827 [erocious-rampage-through-body-brain-toes.](https://www.sciencemag.org/news/2020/04/how-does-coronavirus-kill-clinicians-trace-ferocious-rampage-through-body-brain-toes)
- 828 Wang, B., Wang, L., Kong, X., Geng, J., Xiao, D., Ma, C., *et al.* (2020a). Long-term
829 coexistence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
830 with antibody response in Coronavirus Disease 2019 (COVID-19) Patients. *medRxiv*
831 DOI: <https://doi.org/10.1101/2020041320040980>.
- 832 Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., *et al.* (2020b). Clinical characteristics of
833 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan,
834 China. *JAMA* 323: 1061-1069.
- 835 Wang, G.K., Zhu, J.Q., Zhang, J.T., Li, Q., Li, Y., He, J., *et al.* (2010). Circulating microRNA: a
836 novel potential biomarker for early diagnosis of acute myocardial infarction in humans.
837 *Eur Heart J* 31: 659-666.

- 838 Wang, K., Zhang, S., Marzolf, B., Troisch, P., Brightman, A., Hu, Z., *et al.* (2009). Circulating
839 microRNAs, potential biomarkers for drug-induced liver injury. *Proc Natl Acad Sci U S*
840 *A* 106: 4402-4407.
- 841 Wang, X., Fang, X., Cai, Z., Wu, X., Gao, X., Min, J., and Wang, F. (2020c). Comorbid
842 Chronic Diseases and Acute Organ Injuries Are Strongly Correlated with Disease
843 Severity and Mortality among COVID-19 Patients: A Systemic Review and
844 Meta-Analysis. *Research* 2020: 2402961.
- 845 Wang, X., Xu, W., Hu, G., Xia, S., Sun, Z., Liu, Z., *et al.* (2020d). SARS-CoV-2 infects T
846 lymphocytes through its spike protein-mediated membrane fusion. *Cell Mol Immunol* 7
847 April DOI: 101038/s41423-020-0424-9: 1-3.
- 848 Wang, Z., Wan, Y., Qiu, C., Quinones-Parra, S., Zhu, Z., Loh, L., *et al.* (2015). Recovery from
849 severe H7N9 disease is associated with diverse response mechanisms dominated by
850 CD8(+) T cells. *Nat Commun* 6: 6833.
- 851 WHO (2020). Coronavirus disease 2019 (COVID-19) Situation Report – 131.
- 852 Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., *et al.* (2020a). A new
853 coronavirus associated with human respiratory disease in China. *Nature* 579:
854 265-269.
- 855 Wu, Y., Xu, X., Chen, Z., Duan, J., Hashimoto, K., Yang, L., *et al.* (2020b). Nervous system
856 involvement after infection with COVID-19 and other coronaviruses. *Brain Behav*
857 *Immun.*

- 858 Wynants, L., Van Calster, B., Bonten, M.M., Collins, G.S., Debray, T.P., De Vos, M., *et al.*
859 (2020). Prediction models for diagnosis and prognosis of covid-19 infection:
860 systematic review and critical appraisal. *BMJ* 369: m1328.
- 861 Xiang, P., Xu, X., Gao, L., Wang, H., Xiong, H., and Li, R. (2020). First case of 2019 novel
862 coronavirus disease with Encephalitis. *ChinaXiv* 202003: 00015.
- 863 Xu, W., Wu, J., An, Y., Xiao, C., Hao, F., Liu, H., *et al.* (2012). Streptozotocin-induced
864 dynamic metabonomic changes in rat biofluids. *J Proteome Res* 11: 3423-3435.
- 865 Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., *et al.* (2020). Pathological findings
866 of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med*
867 8: 420-422.
- 868 Zhang, W., Yu, Y., Hertwig, F., Thierry-Mieg, J., Zhang, W., Thierry-Mieg, D., *et al.* (2015).
869 Comparison of RNA-seq and microarray-based models for clinical endpoint prediction.
870 *Genome Biol* 16: 133.
- 871 Zhang, W., Zhang, J., Xu, C., Li, N., Liu, H., Ma, J., *et al.* (2012). LFQ uant: A label-free fast
872 quantitative analysis tool for high-resolution LC-MS/MS proteomics data. *Proteomics*
873 12: 3475-3484.
- 874 Zhao, J., Zhao, J., and Perlman, S. (2010). T cell responses are required for protection from
875 clinical disease and for virus clearance in severe acute respiratory syndrome
876 coronavirus-infected mice. *J Virol* 84: 9318-9325.
- 877 Zheng, Y.-Y., Ma, Y.-T., Zhang, J.-Y., and Xie, X. (2020). COVID-19 and the cardiovascular
878 system. *Nat Rev Cardiol* 17: 259-260.

- 879 Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., *et al.* (2020a). Clinical course and risk factors
880 for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort
881 study. *The Lancet* 395: 1054-1062.
- 882 Zhou, M., Hara, H., Dai, Y., Mou, L., Cooper, D.K., Wu, C., and Cai, Z. (2016). Circulating
883 Organ-Specific MicroRNAs Serve as Biomarkers in Organ-Specific Diseases:
884 Implications for Organ Allo- and Xeno-Transplantation. *Int J Mol Sci* 17.
- 885 Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., *et al.* (2020b). A pneumonia
886 outbreak associated with a new coronavirus of probable bat origin. *Nature* 579:
887 270-273.
- 888 Zhou, Y., Fu, B., Zheng, X., Wang, D., and Zhao, C. (2020c). Pathogenic T cells and
889 inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. *Natl*
890 *Sci Rev* 13 March DOI: 101093/nsr/nwaa041.
- 891 Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., *et al.* (2020). A novel coronavirus
892 from patients with pneumonia in China, 2019. *N Engl J Med*.
- 893 Zou, X., Chen, K., Zou, J., Han, P., Hao, J., and Han, Z. (2020). Single-cell RNA-seq data
894 analysis on the receptor ACE2 expression reveals the potential risk of different human
895 organs vulnerable to 2019-nCoV infection. *Front Med*: 1-8.
- 896

897 **Figure Legends**

898 **Fig. 1 Study design and patient cohort.**

899 (A) Schematic summary of the study design and patient cohort. Total sample numbers before
900 quality control are shown for each omics data set.

901 (B) The number of expressed genes and detected proteins, metabolites, exRNAs and clinical
902 parameters in high quality patient samples.

903 (C) Summary of differentially expressed genes, proteins, metabolites and exRNAs between
904 uninfected controls and COVID-19 patients (mild and severe) in the multi-omics data.

905

906 **Fig. 2 Molecular characteristics of COVID-19 patients.**

907 (A) Scores of principal components 1(PC1) of each sample from the transcriptome, proteome,
908 metabolome, and exRNA-seq principal component analyses.

909 (B) Circos plots showing the significant correlations between clinical parameters and the
910 multi-omics data.

911 (C) The cluster heatmap represents expression patterns in the 1,656, 1,547 and 2,362
912 proteins that showed significant upregulation (fold change>2) in the control, mild and severe
913 patient groups. The top categories enriched for clusters are shown. Values for each protein in
914 all analyzed regions (columns) are color-coded based on expression level, low (blue) and
915 high (red) z-scored FOT.

916 (D) The WGCNA of COVID-19 samples shows modules that are highly correlated with clinical
917 features (left heatmap). Enrichment analysis for different modules is presented in the right

918 heatmap (p value <0.05).

919 (E) Boxplot indicates the APTT time between mild and severe COVID-19 patients. The

920 heatmap indicates the module 1 enriched protein expression patterns among mild and severe

921 patients.

922 (F) Boxplot indicates the IL-6 and IL-10 levels among mild and severe COVID-19 patients.

923 The heatmap indicates the module 2 enriched protein expression patterns among mild and

924 severe patients. Differences between groups were estimated using ANOVA. For all boxplots,

925 the horizontal box lines in the boxplots represent the first quartile, the median, and the third

926 quartile. Whiskers denote the range of points within the first quartile – $1.5\times$ the interquartile

927 range and the third quartile + $1.5\times$ the interquartile range.

928

929 **Fig. 3 Patterns of tissue damage associated with COVID-19.**

930 (A) The distribution of tissue-enhanced proteins across the major tissues affected by

931 COVID-19. Proteins whose expression altered in COVID-19 patients are colored red.

932 (B) Heatmap indicating expression patterns of known tissue specific biomarkers among

933 control, mild and severe patient groups.

934 (C) Systematic summary of brain-enhanced expressed proteins and signaling cascades

935 significantly altered in COVID-19 patients (neurotransmitters transport, synthesis). Values for

936 each protein at all analyzed samples (columns) are color-coded based on the expression

937 level, low (green) and high (red) z-scored FOT.

938 (D) Network summarizing lung-enhanced expressed proteins and signaling cascades

939 significantly altered in COVID-19 patients (HIF-1 α signaling pathway).

940 (E) Network summarizing liver-enhanced expressed proteins and signaling cascades

941 significantly altered in COVID-19 patients (Lipid metabolism).

942 (F) Boxplot indicating the expression level of known brain dysfunctional biomarkers in control,

943 mild and severe patients.

944 (G) Heatmap showing normalized x-cell scores of specific cell types across control, mild and

945 severe COVID-19 patients. * $p < 0.05$ (t test).

946 (H) Heatmap showing the expression of cell type specific signatures among control, mild and

947 severe COVID-19 patients.

948 (I) Systematic summary of the GO pathways enriched by tissue-enhanced proteins that

949 exhibited altered expression among control, mild, and severe patient groups. The heatmap of

950 each panel indicates expression patterns of tissues-enhanced proteins among control, mild,

951 and severe patient groups. The fold changes in tissue-enhanced proteins between

952 mild/severe patient samples and control samples are shown on the right of heatmap.

953

954 **Fig. 4 Differences in immune responses among COVID-19 patients.**

955 (A) Transcriptional profiles reflect the dynamic immune response in COVID-19. GSEA (FDR

956 < 0.25 ; 1,000 permutations) was used to identify positive (red), negative (blue) or no (white)

957 enrichment of BTMs (gene sets). The graph shows the normalized enrichment score (NES) of

958 each selected BTM in the different time points (T1, T2 and T3) for patients with mild or severe

959 COVID-19 illness, in comparison to healthy controls.

960 (B) Expression levels of NETs' markers for individual transcripts in severe versus mild
961 comparisons. Data are represented as means \pm SEM, * $p < 0.05$; *** $p < 0.001$ (t test).
962 (C) Heatmap of *IFNG*, *GZMB* and *PRF1* gene expression in COVID-19 patients.
963 (D) Heatmap of genes enriched in IL-17 signaling pathway between healthy control and
964 COVID-19 patients.
965 (E) T cell and innate immune response elucidate immunopathology of COVID-19.

966

967 **Fig. 5 COVID-19-associated metabolomic changes in blood plasma.**

968 (A) Plasma metabolomic changes revealed a trajectory in COVID-19 severity, from healthy
969 control, mild, to severe.
970 (B) Changes in the concentration of plasma metabolites are associated with COVID-19
971 severity. The discharge group consist of all patients (mild and severe) that were recovered
972 and discharged.
973 (C) COVID-19 severity is associated with significant changes in lipoprotein subclasses
974 including high-density lipoprotein subclass-1 (HDL1), HDL4, low-density lipoprotein
975 subclasses (LDL1, LDL4, LDL5), very low-density lipoprotein subclass-5 (VLDL5) and their
976 compositional components (ApoA1, triglycerides, cholesterol).
977 (D) Plasma levels of key enzymes and proteins directly involving lipoprotein metabolism are
978 indicators for COVID-19 severity. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$ (t test). sLDLR: soluble
979 low density lipoprotein receptor; LCAT: lecithin-cholesterol acyltransferase; CEPT:
980 cholesteryl-ester transfer protein.

981 (E) COVID-19 caused dysregulation in lipoprotein metabolism, glycolysis and TCA cycle. The
982 three boxes from left to right are control, mild and severe, in which gray means normal, blue
983 means decrease, red means increase. H1: HDL1; H3: HDL3; H4: HDL4; L1: LDL1, L3: LDL3;
984 L4: LDL4; L5: LDL5; V1: VLDL1; V4: VLDL4; V5: VLDL5; TG: triglycerides; FC: free
985 cholesterol; CE: cholesteryl esters; CH: total cholesterol (i.e., FC + CE); PL: total
986 phospholipids; H4A1, H4A2: ApoA1 and ApoA2 in HDL4; H-A1, H-A2: ApoA1, ApoA2 (in both
987 HDL and nascent HDL); L1TG: TG in LDL1; L1%: LDL1 percentage in all LDL; TG%, FC%,
988 CE%: percentages of TG, FC and CE, respectively, in total lipids of given lipoprotein
989 subclasses; L-TG/L-CH: TG-to-CH ratio in LDL; H4CH/H4TG: CH-to-TG ratio in HDL4;
990 V1CH/V1TG: CH-to-TG ratio in VLDL1. CS: Citrate synthase; IDH: Isocitrate dehydrogenase;
991 ACO2: Aconitase; OGDH: α -ketoglutarate dehydrogenase; DLD: Dihydrolipoyl
992 dehydrogenase; SDH: Succinic dehydrogenase; MDH: Malate dehydrogenase; PDH:
993 Pyruvate dehydrogenase; PDK: Pyruvate dehydrogenase kinase; ACLY: ATP citrate lyase;
994 ACAC: Acetyl coenzyme A carboxylase; FASN: Fatty acid synthetase; LDH: Lactate
995 dehydrogenase.

996

997 **Fig. 6 Comparative analysis of severe-survival patients and severe-fatal patients**

998 (A) Bar plot comparison of viral loads between severe-survival patients and severe-fatal
999 patients. The cluster heatmap represents expression patterns of 1,541 proteins that exhibited
1000 temporal changes across time points in severe-survival patients. Line graph represents the
1001 temporal changes in viral load in time (days) after hospital admission of the patients.

1002 (B) Enriched annotations for corresponding clusters showed in Fig. 6A.

1003 (C-D) Systematic summary of proteins and signaling cascades significantly altered in

1004 severe-survival patients (lipid metabolism; c) and severe-fatal (viral life cycle; d). Values for

1005 each protein in all samples analyzed (columns) are color-coded based on the expression level,

1006 low (blue) and high (red) z-scored FOT.

1007 (E) For each of the four panels, the heatmaps on the left indicated the Pearson correlation of

1008 proteins with viral load in severe survivors and severe fatalities, the heatmap on the right

1009 indicated the significant pathways enriched by proteins positively or negatively correlated with

1010 viral load in severe survivors and severe fatalities.

1011

1012 **Fig. 7 Biomarkers predictive of clinical outcomes of COVID-19 patients.**

1013 (A) Principal component analysis of exRNA, transcriptome, proteome, and clinical covariate

1014 data from samples collected at the first timepoint. The first two components were used to

1015 describe the distribution of samples based on expressed genes, proteins and clinical data,

1016 respectively, whereas the first and third components were used for samples based on the

1017 exRNA data.

1018 (B) Performance of prognostic models based on exRNA, transcriptome, proteome, and the

1019 corresponding clinical covariate data sets. Model performance of the five-fold cross-validation

1020 was assessed using the Matthews correlation coefficient (MCC), AUC, accuracy, sensitivity,



1021 specificity, positive predictive value (PPV) and negative predictive value (NPV).

1022 (C) The most frequently selected features of exRNA-, transcriptome-, proteome-, and

1023 clinical-based models. Features were simultaneously identified from each of the four data sets
1024 and for each of the four machine learning algorithms based on the frequency of variables
1025 used by AI models during 50 runs of the five-fold cross-validation.

1026 (D) Correlation heatmap among the most frequently selected features (frequency > 0.78)
1027 used in the exRNA-based model. Members in the let-7 family selected for the exRNA-based
1028 predictors (hsa-miR-98-5p, hsa-let-7a-5p, hsa-let-7d-5p, hsa-let-7f-5p) were highly correlated
1029 with each other.

1030 (E-I) Biomarkers identified from exRNA (E), transcriptome (F), proteome (H) and clinical data
1031 (I) based models exhibited a clear separation between those patients with either good or poor
1032 prognosis. (G) Functional enrichment of 110 protein features selected from random forest
1033 modeling.



1

2 **Fig. 1 Study design and patient cohort.**

3 (A) Schematic summary of the study design and patient cohort. Total sample numbers

4 before quality control are shown for each omics data set.


5 (B) The number of expressed genes and detected proteins, metabolites, exRNAs and

6 clinical parameters in high quality patient samples.

7 (C) Summary of differentially expressed genes, proteins, metabolites and exRNAs between

8 uninfected controls and COVID-19 patients (mild and severe) in the multi-omics data.

9




10

11 **Fig. 2 Molecular characteristics of COVID-19 patients.**

- 12 (A) Scores of principal components 1(PC1) of each sample from the transcriptome,
13 proteome, metabolome, and exRNA-seq principal component analyses.
- 14 (B) Circos plots showing the significant correlations between clinical parameters and the
15 multi-omics data.
- 16 (C) The cluster heatmap represents expression patterns in the 1,656, 1,547 and 2,362
17 proteins that showed significant upregulation (fold change>2) in the control, mild and severe
18 patient groups. The top categories enriched for clusters are shown. Values for each protein
19 in all analyzed regions (columns) are color-coded based on expression level, low (blue) and
20 high (red) z-scored FOT.
- 21 (D) The WGCNA of COVID-19 samples shows modules that are highly correlated with
22 clinical features (left heatmap). Enrichment analysis for different modules is presented in the
23 right heatmap (p value <0.05).
- 24 (E) Boxplot indicates the APTT time between mild and severe COVID-19 patients. The
25 heatmap indicates the module 1 enriched protein expression patterns among mild and
26 severe patients.
- 27 (F) Boxplot indicates the IL-6 and IL-10 levels among mild and severe COVID-19 patients.
28 The heatmap indicates the module 2 enriched protein expression patterns among mild and
29 severe patients. Differences between groups were estimated using ANOVA. For all boxplots,
30 the horizontal box lines in the boxplots represent the first quartile, the median, and the third
31 quartile. Whiskers denote the range of points within the first quartile – 1.5× the interquartile
32 range and the third quartile + 1.5× the interquartile range.

33




34

35 **Fig. 3 Patterns of tissue damage associated with COVID-19.**

- 36 (A) The distribution of tissue-enhanced proteins across the major tissues affected by
37 COVID-19. Proteins whose expression altered in COVID-19 patients are colored red.
- 38 (B) Heatmap indicating expression patterns of known tissue specific biomarkers among
39 control, mild and severe patient groups.
- 40 (C) Systematic summary of brain-enhanced expressed proteins and signaling cascades
41 significantly altered in COVID-19 patients (neurotransmitters transport, synthesis). Values for
42 each protein at all analyzed samples (columns) are color-coded based on the expression
43 level, low (green) and high (red) z-scored FOT.
- 44 (D) Network summarizing lung-enhanced expressed proteins and signaling cascades
45 significantly altered in COVID-19 patients (HIF-1 α signaling pathway).
- 46 (E) Network summarizing liver-enhanced expressed proteins and signaling cascades
47 significantly altered in COVID-19 patients (Lipid metabolism).
- 48 (F) Boxplot indicating the expression level of known brain dysfunctional biomarkers in
49 control, mild and severe patients.
- 50 (G) Heatmap showing normalized x-cell scores of specific cell types across control, mild and
51 severe COVID-19 patients. * $p < 0.05$ (t test).
- 52 (H) Heatmap showing the expression of cell type specific signatures among control, mild
53 and severe COVID-19 patients.
- 54 (I) Systematic summary of the GO pathways enriched by tissue-enhanced proteins that
55 exhibited altered expression among control, mild, and severe patient groups. The heatmap of
56 each panel indicates expression patterns of tissues-enhanced proteins among control, mild,

57 and severe patient groups. The fold changes in tissue-enhanced proteins between
58 mild/severe patient samples and control samples are shown on the right of heatmap.
59



60

61 **Fig. 4 Differences in immune responses among COVID-19 patients.**

62 (A) Transcriptional profiles reflect the dynamic immune response in COVID-19. GSEA (FDR

63 < 0.25; 1,000 permutations) was used to identify positive (red), negative (blue) or no (white)

64 enrichment of BTMs (gene sets). The graph shows the normalized enrichment score (NES)

65 of each selected BTM in the different time points (T1, T2 and T3) for patients with mild or


66 severe COVID-19 illness, in comparison to healthy controls.

67 (B) Expression levels of NETs' markers for individual transcripts in severe versus mild

68 comparisons. Data are represented as means ± SEM, **p* < 0.05; ****p* < 0.001 (t test).

- 69 (C) Heatmap of *IFNG*, *GZMB* and *PRF1* gene expression in COVID-19 patients.
- 70 (D) Heatmap of genes enriched in IL-17 signaling pathway between healthy control and
- 71 COVID-19 patients.
- 72 (E) T cell and innate immune response elucidate immunopathology of COVID-19.
- 73

74



75

76 **Fig. 5 COVID-19-associated metabolomic changes in blood plasma.**

77 (A) Plasma metabolomic changes revealed a trajectory in COVID-19 severity, from healthy

78 control, mild, to severe.

79 (B) Changes in the concentration of plasma metabolites are associated with COVID-19

80 severity. The discharge group consist of all patients (mild and severe) that were recovered

81 and discharged.

82 (C) COVID-19 severity is associated with significant changes in lipoprotein subclasses


83 including high-density lipoprotein subclass-1 (HDL1), HDL4, low-density lipoprotein
84 subclasses (LDL1, LDL4, LDL5), very low-density lipoprotein subclass-5 (VLDL5) and their
85 compositional components (ApoA1, triglycerides, cholesterol).

86 (D) Plasma levels of key enzymes and proteins directly involving lipoprotein metabolism are
87 indicators for COVID-19 severity. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$ (t test). sLDLR: soluble
88 low density lipoprotein receptor; LCAT: lecithin-cholesterol acyltransferase; CEPT:
89 cholesteryl-ester transfer protein.

90 (E) COVID-19 caused dysregulation in lipoprotein metabolism, glycolysis and TCA cycle.
91 The three boxes from left to right are control, mild and severe, in which gray means normal,
92 blue means decrease, red means increase. H1: HDL1; H3: HDL3; H4: HDL4; L1: LDL1, L3:
93 LDL3; L4: LDL4; L5: LDL5; V1: VLDL1; V4: VLDL4; V5: VLDL5; TG: triglycerides; FC: free
94 cholesterol; CE: cholesteryl esters; CH: total cholesterol (i.e., FC + CE); PL: total
95 phospholipids; H4A1, H4A2: ApoA1 and ApoA2 in HDL4; H-A1, H-A2: ApoA1, ApoA2 (in
96 both HDL and nascent HDL); L1TG: TG in LDL1; L1%: LDL1 percentage in all LDL; TG%,
97 FC%, CE%: percentages of TG, FC and CE, respectively, in total lipids of given lipoprotein
98 subclasses; L-TG/L-CH: TG-to-CH ratio in LDL; H4CH/H4TG: CH-to-TG ratio in HDL4;
99 V1CH/V1TG: CH-to-TG ratio in VLDL1. CS: Citrate synthase; IDH: Isocitrate dehydrogenase;
100 ACO2: Aconitase; OGDH: α -ketoglutarate dehydrogenase; DLD: Dihydrolipoyl
101 dehydrogenase; SDH: Succinic dehydrogenase; MDH: Malate dehydrogenase; PDH:
102 Pyruvate dehydrogenase; PDK: Pyruvate dehydrogenase kinase; ACLY: ATP citrate lyase;
103 ACAC: Acetyl coenzyme A carboxylase; FASN: Fatty acid synthetase; LDH: Lactate

104 dehydrogenase.

105



106

107

Fig. 6 Comparative analysis of severe-survival patients and severe-fatal patients


108 (A) Bar plot comparison of viral loads between severe-survival patients and severe-fatal
109 patients. The cluster heatmap represents expression patterns of 1,541 proteins that exhibited
110 temporal changes across time points in severe-survival patients. Line graph represents the
111 temporal changes in viral load in time (days) after hospital admission of the patients.

112 (B) Enriched annotations for corresponding clusters showed in Fig. 6A.

113 (C-D) Systematic summary of proteins and signaling cascades significantly altered in severe-
114 survival patients (lipid metabolism; c) and severe-fatal (viral life cycle; d). Values for each
115 protein in all samples analyzed (columns) are color-coded based on the expression level, low
116 (blue) and high (red) z-scored FOT.

117 (E) For each of the four panels, the heatmaps on the left indicated the Pearson correlation of
118 proteins with viral load in severe survivors and severe fatalities, the heatmap on the right
119 indicated the significant pathways enriched by proteins positively or negatively correlated
120 with viral load in severe survivors and severe fatalities.

121



122

123

Fig. 7 Biomarkers predictive of clinical outcomes of COVID-19 patients.

124

(A) Principal component analysis of exRNA, transcriptome, proteome, and clinical covariate

125

data from samples collected at the first timepoint. The first two components were used to

126

describe the distribution of samples based on expressed genes, proteins and clinical data,

127 respectively, whereas the first and third components were used for samples based on the

128 exRNA data.

129 (B) Performance of prognostic models based on exRNA, transcriptome, proteome, and the

130 corresponding clinical covariate data sets. Model performance of the five-fold cross-

131 validation was assessed using the Matthews correlation coefficient (MCC), AUC, accuracy,

132 sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV).

133 (C) The most frequently selected features of exRNA-, transcriptome-, proteome-, and

134 clinical-based models. Features were simultaneously identified from each of the four data

135 sets and for each of the four machine learning algorithms based on the frequency of

136 variables used by AI models during 50 runs of the five-fold cross-validation.

137 (D) Correlation heatmap among the most frequently selected features (frequency > 0.78)

138 used in the exRNA-based model. Members in the let-7 family selected for the exRNA-based

139 predictors (hsa-miR-98-5p, hsa-let-7a-5p, hsa-let-7d-5p, hsa-let-7f-5p) were highly correlated

140 with each other.

141 (E-I) Biomarkers identified from exRNA (E), transcriptome (F), proteome (H) and clinical data

142 (I) based models exhibited a clear separation between those patients with either good or

143 poor prognosis. (G) Functional enrichment of 110 protein features selected from random

144 forest modeling.